Quarterly report · Q2

Period2021-12-01 → 2022-05-31
Filed2022-07-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥3.9bn2021-12-01 → 2022-05-31Cons.Net sales
Revenue¥7.9bn2020-12-01 → 2021-11-30Cons.Net sales (5-year summary)
Revenue¥3.9bn2020-12-01 → 2021-05-31Cons.Net sales
Operating income¥226m2021-12-01 → 2022-05-31Cons.Operating income
Operating income¥270m2020-12-01 → 2021-05-31Cons.Operating income
Ordinary income¥235m2021-12-01 → 2022-05-31Cons.Ordinary income
Ordinary income¥386m2020-12-01 → 2021-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥273m2020-12-01 → 2021-05-31Cons.Ordinary income
Profit before tax¥234m2021-12-01 → 2022-05-31Cons.Income before income taxes
Profit before tax¥273m2020-12-01 → 2021-05-31Cons.Income before income taxes
Net income (owners)¥179m2021-12-01 → 2022-05-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥281m2020-12-01 → 2021-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥195m2020-12-01 → 2021-05-31Cons.Profit loss attributable to owners of parent
Net income¥179m2021-12-01 → 2022-05-31Cons.Profit loss
Net income¥195m2020-12-01 → 2021-05-31Cons.Profit loss
Total assets¥7.8bnat 2022-05-31Cons.Assets
Total assets¥7.9bnat 2021-11-30Cons.Assets
Total assets¥7.6bnat 2021-05-31Cons.Total assets (5-year summary)
Total liabilities¥5.4bnat 2022-05-31Cons.Liabilities
Total liabilities¥5.6bnat 2021-11-30Cons.Liabilities
Net assets / equity¥2.4bnat 2022-05-31Cons.Net assets
Net assets / equity¥2.3bnat 2021-11-30Cons.Net assets
Net assets / equity¥2.2bnat 2021-05-31Cons.Net assets (5-year summary)
Cash and deposits¥984mat 2022-05-31Cons.Cash and deposits
Cash and deposits¥1.3bnat 2021-11-30Cons.Cash and deposits
Cash & equivalents¥984mat 2022-05-31Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2021-11-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2021-05-31Cons.Cash and cash equivalents
Cash & equivalents¥883mat 2020-11-30dCons.Cash and cash equivalents
Operating cash flow−¥124m2021-12-01 → 2022-05-31Cons.Net cash provided by used in operating activities
Operating cash flow¥785m2020-12-01 → 2021-11-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥388m2020-12-01 → 2021-05-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥121m2021-12-01 → 2022-05-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥246m2020-12-01 → 2021-11-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥109m2020-12-01 → 2021-05-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥104m2021-12-01 → 2022-05-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥119m2020-12-01 → 2021-11-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥78m2020-12-01 → 2021-05-31Cons.Net cash provided by used in financing activities
EPS (basic)¥147.062021-12-01 → 2022-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.822022-03-01 → 2022-05-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥230.992020-12-01 → 2021-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥160.32020-12-01 → 2021-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥95.622021-03-01 → 2021-05-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.6%at 2022-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio28.5%at 2021-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio28.5%at 2021-05-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2021-12-01 → 2022-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2021-12-01 → 2022-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2021-12-01 → 2022-05-31¥211m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2021-12-01 → 2022-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2021-12-01 → 2022-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2021-12-01 → 2022-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2021-12-01 → 2022-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-12-01 → 2022-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-12-01 → 2022-05-31¥226m
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2020-12-01 → 2021-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2020-12-01 → 2021-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2020-12-01 → 2021-05-31¥255m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2020-12-01 → 2021-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2020-12-01 → 2021-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2020-12-01 → 2021-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2020-12-01 → 2021-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2020-12-01 → 2021-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2020-12-01 → 2021-05-31¥270m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 477
ItemContextValueUnit
Increase decrease in allowance for doubtful accounts ope cfPrior1YTDDuration-821000JPY
Increase decrease in allowance for doubtful accounts ope cfCurrentYTDDuration-89000JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration-39103000JPY
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration-256000JPY
Increase decrease in provision for directors bonuses ope cfPrior1YTDDuration-1500000JPY
Increase decrease in provision for directors bonuses ope cfCurrentYTDDuration-13800000JPY
Increase decrease in provision for directors retirement benefits ope cfPrior1YTDDuration11673000JPY
Increase decrease in provision for directors retirement benefits ope cfCurrentYTDDuration-29150000JPY
Interest and dividends income ope cfPrior1YTDDuration-1128000JPY
Interest and dividends income ope cfCurrentYTDDuration-2281000JPY
Foreign exchange losses gains ope cfPrior1YTDDuration-152000JPY
Foreign exchange losses gains ope cfCurrentYTDDuration-100000JPY
Interest expenses paid on loans and bonds ope cfPrior1YTDDuration8690000JPY
Interest expenses paid on loans and bonds ope cfCurrentYTDDuration8797000JPY
Loss on retirement of noncurrent assets ope cfPrior1YTDDuration2352000JPY
Loss on retirement of noncurrent assets ope cfCurrentYTDDuration1736000JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration-207596000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration52371000JPY
Decrease increase in inventories ope cfPrior1YTDDuration-49487000JPY
Decrease increase in inventories ope cfCurrentYTDDuration-372913000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YTDDuration293669000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration28004000JPY
Increase decrease in accrued consumption taxes ope cfPrior1YTDDuration-63072000JPY
Increase decrease in accrued consumption taxes ope cfCurrentYTDDuration-38468000JPY
Other net ope cfPrior1YTDDuration-13995000JPY
Other net ope cfCurrentYTDDuration-101200000JPY
Subtotal ope cfPrior1YTDDuration398701000JPY
Subtotal ope cfCurrentYTDDuration-38207000JPY
Interest and dividends income received ope cf inv cfPrior1YTDDuration1128000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration2281000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-8667000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-8773000JPY
Income taxes paid ope cfPrior1YTDDuration-3355000JPY
Income taxes paid ope cfCurrentYTDDuration-79585000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration387806000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration-124285000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-119884000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-122749000JPY
Purchase of intangible assets inv cfPrior1YTDDuration-2200000JPY
Purchase of intangible assets inv cfCurrentYTDDuration-1800000JPY
Collection of loans receivable inv cfPrior1YTDDuration8000000JPY
Collection of loans receivable inv cfCurrentYTDDuration-JPY
Other net inv cfPrior1YTDDuration4982000JPY
Other net inv cfCurrentYTDDuration3929000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-109102000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-120620000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-36658000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-36658000JPY
Repayments of lease obligations fin cfPrior1YTDDuration-4699000JPY
Repayments of lease obligations fin cfCurrentYTDDuration-6910000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2021-11-30pass
balance sheet identityconsolidated 2022-05-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-11-30pass
statement vs summary · net assetsconsolidated 2022-05-31pass
statement vs summary · net income attributable to parentconsolidated 2020-12-01/2021-05-31pass
statement vs summary · net income attributable to parentconsolidated 2021-12-01/2022-05-31pass
statement vs summary · operating cash flowconsolidated 2020-12-01/2021-05-31pass
statement vs summary · operating cash flowconsolidated 2021-12-01/2022-05-31pass
statement vs summary · revenueconsolidated 2020-12-01/2021-05-31pass
statement vs summary · revenueconsolidated 2021-12-01/2022-05-31pass
statement vs summary · total assetsconsolidated 2021-11-30pass
statement vs summary · total assetsconsolidated 2022-05-31pass